Anna R. Kwilas

发表

In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer

M. Bernstein, R. Donahue, J. Hodge, 2012, Front. Oncol..

IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas

J. Schlom, H. Wong, P. Kim, 2016, Oncotarget.

Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine

Andressa Ardiani, R. Donahue, J. Hodge, 2014, Journal of Translational Medicine.

The generation and analysis of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic

J. Schlom, A. Rice, R. Madan, 2015, Journal of Immunotherapy for Cancer.

The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic

J. Schlom, A. Rice, R. Madan, 2015, Oncotarget.

The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

Andressa Ardiani, J. Hodge, B. Farsaci, 2012, Seminars in oncology.

Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process.

J. Schlom, Andressa Ardiani, J. Hodge, 2014, Cancer research.

Design, development and translation of poxvirus-based vaccines for cancer

J. Hodge, A. Kwilas, B. Farsaci, 2011 .

Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy.

K. Tsang, R. Donahue, J. Hodge, 2015, Cancer cell & microenvironment.

Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack

R. Donahue, J. Hodge, I. Grenga, 2015, Journal of Immunotherapy for Cancer.

Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway

Andressa Ardiani, R. Donahue, J. Hodge, 2014, Oncotarget.

Overview of the US Food and Drug Administration Regulatory Process

J. Arcidiacono, D. Kaplan, R. Mcfarland, 2019, Principles of Regenerative Medicine.

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells

M. Brechbiel, J. Schlom, R. Madan, 2016, Oncotarget.

Treatment with the IDO inhibitor INCB024360 increased lysis of human tumor cell targets by peptide-specific CTL

M. Brechbiel, J. Schlom, P. Kim, 2015, Journal of Immunotherapy for Cancer.

A poxviral-based cancer vaccine targeting the transcription factor Twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer model

Andressa Ardiani, J. Hodge, U. Dirmeier, 2015, Oncotarget.

Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin

Andressa Ardiani, Jacob Richards, J. Hodge, 2016, Oncotarget.

Design and Testing of Vector-Producing HEK293T Cells Bearing a Genomic Deletion of the SV40 T Antigen Coding Region

J. Chiorini, J. Reiser, S. Afione, 2020, Molecular therapy. Methods & clinical development.

Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets

A. Dicker, J. Hodge, S. Gameiro, 2014, British Journal of Cancer.

In vivo targeting of lentiviral vectors pseudotyped with the Tupaia paramyxovirus H glycoprotein bearing a cell-specific ligand

J. Reiser, W. Ou, K. Takeda, 2021, Molecular therapy. Methods & clinical development.